In the United Kingdom, a debate is emerging over the preferred medical approach to treating obesity amid the rapid rise in use of GLP-1 weight-loss injections such as Mounjaro and Wegovy. With an estimated 2.5 million people having taken these drugs, which mimic gut hormones to suppress appetite, their popularity has soared following clinical studies showing significant weight reduction. A 2024 study published in JAMA reported an average body weight loss of 20% after nine months on tirzepatide, the active ingredient in Mounjaro. However, real-world results indicate a considerable portion of users—between 10 and 15%—experience minimal or no benefit, and many discontinue treatment due to side effects such as nausea and diarrhea.

Researchers are investigating factors behind variable responses to GLP-1 drugs, including the potential influence of hormones such as oestrogen and genetic differences. Studies have noted enhanced results in pre-menopausal women and those on hormone replacement therapy compared to men or post-menopausal women. Yet concerns remain that the prominence of these medications may be overshadowing other effective weight-loss treatments, notably bariatric surgery and older pharmaceutical options like Mysimba, a less expensive drug recommended for mild obesity.

Bariatric surgery, which typically includes procedures like gastric sleeve and gastric bypass, is widely regarded by specialists as a highly effective long-term solution for severe obesity. Despite advancements that allow many surgeries to be conducted via minimally invasive keyhole techniques, the volume of procedures in the UK has declined sharply over recent years. Data from the Private Healthcare Information Network shows gastric sleeve operations have decreased by 67% and gastric bypasses by 79% between 2023 and 2025. The National Health Service (NHS) has similarly experienced a drop, with current annual operations estimated at 5,000 to 6,000—down from 8,000 in 2018–2019. Experts note that only about 1% of the 4.2 million UK residents eligible for surgery under NHS criteria receive it.

Eligibility for NHS bariatric surgery requires a body mass index (BMI) of 40 or above, or 35 with obesity-related conditions such as type 2 diabetes. For GLP-1 medications on the NHS, the criteria are often stricter, demanding a BMI of 40 or higher plus multiple weight-related health issues. Specialists warn that many patients who do not respond to, cannot tolerate, or cannot afford the drugs may miss out on surgery’s more substantial and lasting benefits. Bariatric surgery consistently results in an average of 30% weight loss over two years, with many patients retaining this reduction long term, while GLP-1 treatments typically produce smaller losses that depend on ongoing medication use.

Surgeons also highlight the significant health improvements achieved through surgery, including rapid remission of type 2 diabetes and resolution of conditions like high blood pressure and sleep apnea. However, surgery carries inherent risks, including a complication rate of approximately 2.4%, with potential early issues such as infection and blood clots, and late complications like nutrient deficiencies if patients fail to follow up properly. Weight-loss drugs, while less invasive, are associated with side effects and muscle loss, which may be greater than that seen after surgery.

An alternative surgical method, the endoscopic gastric sleeve, performed without external incisions via a tube down the throat, offers weight loss between 15 and 20%. Although approved by the National Institute for Health and Care Excellence (NICE), this procedure is only available in select NHS centers and costs around £10,000 privately, compared to roughly £3,000 annually for GLP-1 drugs.

From a cost perspective, bariatric surgery is viewed by some as a more economical option over time, given that lengthy pharmaceutical treatment may require indefinite expenditure. Experts argue that the high marketing budgets of pharmaceutical companies contribute to the prominence of GLP-1 drugs, while surgery receives little promotional support. This disparity, alongside confusion over eligibility criteria, has led some local health authorities to hesitate in funding any obesity treatments.

Beyond surgery and medication, other NHS programs such as the Type 2 Diabetes Path to Remission—which involves a low-calorie diet followed by gradual food reintroduction—show promise in managing obesity and related conditions but tend to receive less attention.

Experts caution that neither pharmacological nor surgical options serve as a universal solution for obesity. Dr. Jack Doughty of the Obesity Health Alliance emphasizes the importance of integrating treatment with broader prevention strategies, while Professor Alexander Miras from the University of Ulster notes that although initial demand for bariatric surgery declined with GLP-1 availability, it is rising again in countries like Norway. He points out the limited NHS access and sustainability concerns with long-term drug use, underscoring surgery’s role as a permanent intervention.

Professor Ahmed Ahmed of Imperial College Healthcare NHS Trust is advocating for a comparative clinical trial to evaluate the outcomes, quality of life, and cost-effectiveness of injections versus surgery. He highlights the need for clear evidence to guide NHS resource allocation amid competing obesity treatments.

As the medical community continues to assess the evolving landscape of obesity management, the consensus remains that a personalized, multifaceted approach—including medication, surgery, and lifestyle modification—will be essential to address the growing health burden posed by obesity in the UK.